The $119.5 billion cystic fibrosis franchise is being deliberately de-risked: management now counts rare…

Earnings · 2026 Q2 Reshma Kewalramani CEO

Aug 3, 4:09pm ET

“Vertex delivered excellent second quarter results, expanding our leadership in cystic fibrosis; delivering strong revenue growth in sickle cell disease, beta thalassemia, and acute pain; and with the pending acquisition of Crinetics, adding rare endocrine diseases as our fifth pillar, further diversifying our portfolio.

The $119.5 billion cystic fibrosis franchise is being deliberately de-risked: management now counts rare endocrine disease as a fifth revenue pillar once Crinetics closes, alongside sickle cell, beta thalassemia and acute pain. For anyone still valuing Vertex as a single-disease company, the pillar count is the number to track.